The firm said investors are overlooking some ‘exciting’ treatments ahead for glaucoma, corneal disorders and other retinal diseases.
You are here: Home / This medtech stock has a ‘pathway to $1B in sales’ by 2030, Piper Sandler says
Market News and Views
The firm said investors are overlooking some ‘exciting’ treatments ahead for glaucoma, corneal disorders and other retinal diseases.